• Home
  • About
  • SOM
  • Career
  • Classroom
  • Community
  • Store
  • Cart

  • Login
AADNS
  • Membership
    • Member Central
    • Benefits
    • Join
    • Refer
    • Students
    • Member Discount Programs
    • Membership FAQs
    • Awards and Grants
  • Education
    • DNS Fundamentals
    • DNS-CT Certification
    • QCP Certification
    • Recertifications
    • MDS 101
    • Staff In-Service Education
    • Survey Readiness 24/7 Toolkit
    • Documentation Toolkit
  • Resources
    • Resource Library
    • News Feed
    • Patient-Driven Payment Model (PDPM)
    • DNS Body of Knowledge
    • Tools
    • SOM
    • Government Documents
    • DNS Navigator
    • DNS Starter Kit
    • Nurse Leader Blog
    • LTC DON Chat Podcast
  • Events
    • Live Workshops
    • Live & On-Demand Webinars
    • Annual Conference
    • Master Teacher Information
  • Networking
    • Connected Community
    • Volunteer
  • Business Partners
    • Partner Directory

You Are Here:Home/Resources/Risk Management/Risk Management Details

Other Topics

  • Nursing Leadership
  • Patient-Driven Payment Model
  • Infection Prevention and Control
  • Clinical Surveillance of Nursing Systems
  • QAPI
  • Human Resources
  • Survey Readiness and Management
  • Risk Management
  • Corporate Compliance
  • Billing and Payment Initiative
  • World Health Organization: Updated COVID-19 Interim Guidance for LTC Facilities (1/21)

    Tuesday, January 12, 2021 | WHO
    Infection prevention and control guidance for long-term care facilities (including NFs and SNFs) in the context of COVID-19 Interim guidance

    8 January 2021

    This document is an update of the guidance published on 21 March 2020 and contains new evidence and guidance, including the following:

    • updated results from published studies on:
      • the epidemiology and extent of SARS-CoV-2 infection among residents and staff in long-term care facilities (LTCFs);
      • the effectiveness of infection prevention and control (IPC) precautions to prevent SARS-CoV-2 transmission in LTCFs;
      • the impact of IPC precautions on mental and physical health and well-being of older people, and in particular people with dementia or other mental health or neurological disorders;
    • updated advice on IPC precautions to prevent the spread of SARS-CoV-2 and to protect health workers and caregivers of patients with suspected or confirmed COVID-19 in LTCFs;
    • advice on early detection of and testing for SARS-CoV-2 among residents and staff in LTCFs;
    • advice on policies for visitors to LTCFs and additional considerations on minimizing the mental and physical health impacts of restrictions and IPC precautions implemented in the context of COVID-19.
    Read more
    Category:
    • Resident Care
    • Risk Management
    • Clinical Surveillance
    • Infection Prevention and Control (IPC)
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Infection/Infection Control
    • Evidence-Based Practice
    • NAC
    • Clinical Surveillance
    • DNS
    • infections/infection control
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • FDA Alert: SARS-CoV-2 Viral Mutation Could Cause False Negatives on Tests, but Overall Risk Is Low (1/21)

    Monday, January 11, 2021 | FDA

    The U.S. Food and Drug Administration is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus’s genome assessed by that test. The SARS-CoV-2 virus can mutate over time, like all viruses, resulting in genetic variation in the population of circulating viral strains, as seen with the B.1.1.7 variant. The FDA is taking additional actions to ensure authorized tests remain accurate by working with test developers and conducting ongoing data analysis to evaluate all currently authorized molecular tests. The FDA believes the risk that these mutations will impact overall testing accuracy is low.

    “The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients,” said FDA Commissioner Stephen M. Hahn, M.D. “While these efforts continue, we are working with authorized test developers and reviewing incoming data to ensure that health care providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with emerging genetic variants. At this time, we believe the data suggests that the currently authorized COVID-19 vaccines may still be effective against this strain. The FDA will continue to keep health care providers and the public informed of any new information as it becomes available.”

    The FDA has been monitoring SARS-CoV-2 viral mutations, and potential impact on testing, throughout the pandemic. The presence of SARS-CoV-2 genetic variants in a patient sample can potentially change the performance of a SARS-CoV-2 test. Tests that rely on the detection of multiple regions of the genome may be less impacted by genetic variation in the SARS-CoV-2 genome than tests that rely on detection of only a single region.

    Three currently authorized molecular tests, MesaBiotech Accula, TaqPath COVID-19 Combo Kit, and Linea COVID-19 Assay Kit, may be impacted by genetic variants of SARS-CoV-2, but the impact does not appear to be significant. Importantly, the detection pattern that appears with the TaqPath and Linea diagnostic tests when certain genetic variants are present may help with early identification of new variants in patients to reduce further spread of infection. The recently identified B.1.1.7 variant has been associated with an increased risk of transmission, therefore early identification of this variant in patients may help reduce further spread of infection.

    The FDA has reminded clinical laboratory staff and health care providers about the risk of false negative results with all laboratory tests, including molecular tests. Laboratories should expect some false results to occur even when very accurate SARS-CoV-2 tests are used. Today’s announcement also provides important information and recommendations for clinical laboratory staff and health care providers who use molecular tests for the detection of SARS-CoV-2.

    The FDA will continue to communicate with the public as we have additional information to share. The FDA encourages stakeholders to report any adverse events or suspected adverse events experienced with molecular tests for detection of SARS-CoV-2. Voluntary reports can be submitted through MedWatch, the FDA Safety Information and Adverse Event Reporting program. Health care personnel and clinical laboratory staff employed by facilities that are performing COVID-19 testing should follow the reporting requirements for authorized laboratories as specified in the test’s Emergency Use Authorization. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices.

    ###



    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    • Staff Leadership and Management
    • Infection Prevention and Control (IPC)
    Tags:
    • Articles & Information
    • DON
    • Staff Leadership and Management
    • Need to Know
    • Risk Management
    • Infection/Infection Control
    • NAC
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • National Healthcare Safety Network (NHSN) Long-term Care Facility COVID-19 Reporting Module Website UPDATED (1/21)

    Sunday, January 10, 2021 | CDC

    CDC’s NHSN provides healthcare facilities, such as long-term care facilities (LTCFs), with a customized system to track infections and prevention process measures in a systematic way. Tracking this information allows facilities to identify problems, improve care, and determine progress toward national healthcare-associated infection goals.

    The NHSN Long-term Care Facility Component is supporting the nation’s COVID-19 response through the COVID-19 Module for LTCFs. Facilities eligible to report into the COVID-19 Module include nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities.

    The COVID-19 Module for LTCFs consists of four pathways within NHSN’s Long-term Care Facility Component:

    • Resident Impact and Facility Capacity
    • Staff and Personnel Impact
    • Supplies and Personal Protective Equipment
    • Ventilator Capacity and Supplies

    Data submitted into the Module pathways enables an assessment of the impact of COVID-19 through facility reported information, including: 1) counts of residents and facility personnel with newly suspected and laboratory positive COVID-19; 2) death counts among residents and facility personnel with suspected and laboratory positive COVID-19; 3) staffing shortages; 4) availability of personal protective equipment (PPE) and supplies; and 5) ventilator capacity and supplies for facilities with ventilator dependent units.

    In addition to the reporting pathways, the Point-of-Care (POC) Test Reporting Tool has been added to enable LTCFs to enter POC SARS-CoV-2 test results into the NHSN application.  NHSN will route the POC laboratory test data to the public health agency at the local or state level that has jurisdictional authority and responsibility to receive those data.  Health agencies, in turn, will use the data to fulfill their public health functions, which include reporting to the US Department of Health and Human Services, where the data will be used in the COVID-19 response. Participation in this pathway requires users to have secure access through Secure Access Management Services (SAMS), which includes having a SAMS grid card.

    LTCF data submission options include manual entry and/or CSV file submitted by individual facilities or bulk CSV file upload for multiple facilities. Note: CSV file submission is not currently available for the Point-of-Care (POC) Test Reporting Tool.


    Read more
    Category:
    • Risk Management
    • Survey Management
    • Clinical Surveillance
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Survey Readiness
    • Risk Management
    • Infection/Infection Control
    • NAC
    • Clinical Surveillance
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • CDC COVID-19 Vaccination Toolkit for SNFs/NFs (1/21)

    Tuesday, January 5, 2021 | CDC

    Long-Term Care Facility Toolkit: Preparing for COVID-19 Vaccination at Your Facility

    Answering Common Questions About COVID-19 Vaccines

    This toolkit provides long-term care facility (LTCF) administrators and clinical leadership with information and resources to help build vaccine confidence among healthcare personnel (HCP) and residents. You play a critical role in providing trusted information and ensuring high COVID-19 vaccination coverage in your facility.

    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    • Staff Leadership and Management
    • Infection Prevention and Control (IPC)
    Tags:
    • Articles & Information
    • DON
    • Staff Leadership and Management
    • Need to Know
    • Survey Readiness
    • Risk Management
    • Infection/Infection Control
    • NAC
    • Immunizations
    • DNS
    • infections/infection control
    • Resident Care
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • COVID-19 Vaccinations: Importance for Residents and Staff (12/20)

    Tuesday, December 29, 2020 | CDC

    CDC provides information on COVID-19 vaccinations for residents and staff:

    • Importance of COVID-19 Vaccination for Residents of Long-term Care Facilities
    • The Importance of COVID-19 Vaccination for Healthcare Personnel
    Read more
    Category:
    • Resident Care
    • Nursing Leadership
    • Risk Management
    • Survey Management
    • Infection Prevention and Control (IPC)
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Infection/Infection Control
    • NAC
    • Immunizations
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • Considerations for Use of SARS-CoV-2 Antigen Testing in Nursing Homes (12/20)

    Monday, December 28, 2020 | CDC
    This document provides a summary of considerations for use of SARS-CoV-2 (the virus that causes COVID-19) antigen testing in nursing homes and is intended for nursing home providers and state and local public health departments.

    Also see: Guidance for SARS-CoV-2 Point-of-Care Testing

    UPDATE: 


    As of December 28, 2020

    • Updated To whom long-term care facilities (LCTFs) should report point-of-care antigen testing data under “Reporting requirements for SARS-CoV-2 tests”
    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    • Clinical Surveillance
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Infection/Infection Control
    • Evidence-Based Practice
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • ACIP Interim Recommendation for Use of Pfizer-BioNTech and Moderna COVID-19 Vaccines (12/20)

    Thursday, December 24, 2020 | CDC
    The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 Early Release / December 13, 2020 / 69


    Summary

    What is already known about this topic?

    On December 11, 2020, the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine.

    What is added by this report?

    On December 12, 2020, after an explicit, evidence-based review of all available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.

    What are the implications for public health practice?

    The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP’s interim recommendation for allocating initial supplies of COVID-19 vaccines.


    The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020

    Summary

    What is already known about this topic?

    On December 18, 2020, the Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 vaccine.

    What is added by this report?

    On December 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19.

    What are the implications for public health practice?

    Use of all COVID-19 vaccines authorized under an EUA, including the Moderna COVID-19 vaccine, should be implemented in conjunction with ACIP’s interim recommendations for allocating initial supplies of COVID-19 vaccines.

     


    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    • Infection Prevention and Control (IPC)
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Survey Readiness
    • Infection/Infection Control
    • Evidence-Based Practice
    • Immunizations
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • CDC Strategies for Optimizing the Supply of PPE and Other Equipment (12/20)

    Tuesday, December 22, 2020 | CDC

    The Centers for Disease Control and Prevention (CDC) offers strategies for optimizing the supply of:

    N95 respirators

    Face masks

    Isolation gowns

    Eye Protection

    Gloves

    Powered Air-Purifying Respirators (PAPRs)

    Elastomeric respirators

    Ventilators

    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    Tags:
    • Articles & Information
    • DON
    • Need to Know
    • Survey Readiness
    • Risk Management
    • Infection/Infection Control
    • Emergency Preparedness
    • NAC
    • DNS
    Comments (0)
  • Dec. 22 CMS-CDC Nursing Home Stakeholder Call on COVID-19 Vaccinations

    Monday, December 21, 2020 | CMS and the CDC

    Date:                          Tuesday, December 22

    Time:                          1:00 – 2:00 pm ET

    Toll Free Dial-In:       833-614-0820  

    Access Passcode:     7979889

    Overview: Please join CDC and CMS for this call with Nursing Homes focused on COVID 19 vaccination among residents and staff. During this call, you’ll receive:

     

    ·         Updates on Pharmacy Partnership for Long-Term Care Program;

    ·         Critical clinical, safety, and infection prevention and control considerations associated with implementation;

    ·         Communication resources you can use to address resident and staff questions and concerns; and

    ·         General reminders for the holiday season.

    ·         A questions and answer session will follow updates.

     

    Conference lines are limited. We encourage you to join via audio webcast, either on your computer or smartphone web browser. These calls are not intended for the press.

     

    For More Information:

    ·         Coronavirus.gov

    ·         CMS Current Emergencies

    ·         Podcast and Transcripts  view transcripts and listen to audio recordings of COVID-19 calls

    ·         Coronavirus (COVID-19) Partner Toolkit view this webpage for the most current information including call schedule changes.

     

     


    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    • Staff Leadership and Management
    • Infection Prevention and Control (IPC)
    Tags:
    • DON
    • CMS Updates & Regulations
    • Need to Know
    • Infection/Infection Control
    • NAC
    • Immunizations
    • DNS
    • infections/infection control
    • COVID-19
    • Infection Preventionist
    • Infection Prevention and Control Program (IPCP)
    Comments (0)
  • AHRQ Study: Transforming Medication Regimen Review With Telemedicine to Prevent Adverse Events (12/20)

    Monday, December 21, 2020 | AHRQ
    Transforming the medication regimen review process using telemedicine to prevent adverse events

    AHRQ News Now:

    Kane‐Gill SL, Wong A, Culley CM, et al. J Am Geriatr Soc. 2020;Epub Nov 25.

    Medication reconciliation and medication regimen reviews can reduce adverse drug events (ADEs) in older adults. This study assessed the impact of a pharmacist-led, patient-centered telemedicine program to manage high-risk medications during transitional and nursing home care. The program included telemedicine-based medication reconciliation at admission and medication regimen reviews throughout the nursing home stay, coupled with clinical decision support. Residents in the program experienced fewer adverse drug events compared to a usual care group. This innovative model has the potential to further reduce medication errors in nursing home residents.

    Read more
    Category:
    • Resident Care
    • Risk Management
    • Survey Management
    Tags:
    • Articles & Information
    • DON
    • Unnecessary Drugs (Medication Management)
    • Need to Know
    • Survey Readiness
    • Evidence-Based Practice
    • DNS
    • Medication Errors
    Comments (0)

Oops! This is member-only content.


To access this resource, please login or sign up for a membership. 

  • Sign In
  • New Account
  • Forgot Password
  • Membership
    • Member Central
    • Benefits
    • Join
    • Refer
    • Students
    • Member Discount Programs
    • Membership FAQs
    • Awards and Grants
  • Education
    • DNS Fundamentals
    • DNS-CT Certification
    • QCP Certification
    • Recertifications
    • MDS 101
    • Staff In-Service Education
    • Survey Readiness 24/7 Toolkit
    • Documentation Toolkit
  • Resources
    • Resource Library
    • News Feed
    • Patient-Driven Payment Model (PDPM)
    • DNS Body of Knowledge
    • Tools
    • SOM
    • Government Documents
    • DNS Navigator
    • DNS Starter Kit
    • Nurse Leader Blog
    • LTC DON Chat Podcast
  • Events
    • Live Workshops
    • Live & On-Demand Webinars
    • Annual Conference
    • Master Teacher Information
  • Networking
    • Connected Community
    • Volunteer
  • Business Partners
    • Partner Directory

Contact Info

American Association of Directors of Nursing Services (AADNS)
400 S. Colorado Blvd, Ste 600
Denver, CO 80246

Phone: 720.379.6739
Toll-free: 844.796.9634
Fax: 303.758.3588
Email: Contact Us

Stay Connected

  • Facebook
  • Pinterest
  • LinkedIn
  • AADNSNetwork
  • Twitter
search
Copyright © 2021 American Association of Post-Acute Care Nursing (AAPACN)
  • Legal Notices/Privacy Policy
  • Contact Us
  • Back to Top